Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth Conference

^
DGAP-News: Laxxon Medical / Schlagwort(e): Sonstiges
Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth
Conference

07.01.2022 / 11:15
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

NEW YORK, NY / ACCESSWIRE / January 7, 2022 / Laxxon Medical Corporation
announced today that management will conduct one-on-one meetings at the 24th
Annual Needham Growth Conference, which will be held virtually from Jan
10-14, 2022.

About Laxxon Medical Corporation

Laxxon Medical holds the exclusive worldwide rights to the patented use and
application of 3D screen printing technology for the development,
manufacture and commercialization of pharmaceutical dosage forms.

With Laxxon Medical's innovative SPID(R)-Technology (Screen Printing
Innovational Drug Technology), it is possible for the first time to develop
oral, transdermal and implantable dosage forms through geometric shaping and
heterogeneous distribution of active ingredients within the printed units
yielding dosage forms with tailored release of active ingredients.

To learn more about Laxxon Medical's disruptive 3D screen printing
technology, visit www.laxxonmedical.com.

Contact:

Frances Hoggard, Public Relations Manager
f.hoggard@laxxon-medical.com

SOURCE: Laxxon Medical Corporation


---------------------------------------------------------------------------

07.01.2022 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de

---------------------------------------------------------------------------

   Sprache:        Deutsch
   Unternehmen:    Laxxon Medical
                   135 E 57th St., 14th Floor
                   10022 New York
                   Vereinigte Staaten von Amerika
   EQS News ID:    1266336



   Ende der Mitteilung    DGAP News-Service
---------------------------------------------------------------------------

1266336 07.01.2022

°